Premium
The effects of cimetidine on serum calcium and parathyroid hormone levels in primary hyperparathyroidism.
Author(s) -
Fisken RA,
Wilkinson R.,
Heath DA
Publication year - 1982
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1982.tb04960.x
Subject(s) - cimetidine , parathyroid hormone , primary hyperparathyroidism , medicine , hyperparathyroidism , endocrinology , calcium , placebo , drug , secondary hyperparathyroidism , pharmacology , alternative medicine , pathology
1 Cimetidine has been reported to reduce serum calcium and parathyroid hormone (PTH) levels in primary hyperparathyroidism, but some studies have reported negative findings. 2 A double‐blind, controlled trial of cimetidine in this condition was, therefore, conducted. Eight patients were given cimetidine and placebo for 2 months each, in random order. Only one patient showed a significant fall in serum calcium on cimetidine and no patient showed a fall in PTH levels. 3 In addition, eight patients were studied during a 48 h continuous intravenous infusion of cimetidine. The first five patients exhibited no effect of the drug on either calcium of PTH levels, but in the sixth there appeared to be a dose‐dependent suppression of PTH. The seventh and eighth patients were, therefore, given a higher dose of the drug but it failed to suppress calcium or PTH values. 4 It is concluded that cimetidine is not of value in primary hyperparathyroidism.